We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A judge dismissed claims that the FDA is precluded from approving generic versions of Otsuka’s blockbuster antipsychotic until its orphan exclusivity expires. Read More
The FDA is still not convinced that Sprout Pharmaceutical’s libido-enhancing drug for women is safe, particularly when mixed with alcohol, and has asked two of its advisory committees to consider whether alcohol should be contraindicated in the product’s labeling. Read More
The UK’s National Institute for Health and Care Excellence confirmed its recommendations for Bayer’s Eylea and Allergan’s Ozurdex for some patients with diabetic macular edema in separate final draft guidances. Read More
The high cost of AstraZeneca’s ovarian cancer treatment Lynparza doesn’t match the uncertainty of its survival benefits, the UK’s healthcare cost agency says. Read More
Upsher-Smith’s Qudexy XR is now available as a first-line monotherapy for children ages two and older who have partial-onset or tonic-clonic seizures. Read More